Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESONATE: Ibrutinib vs Ofatumumab in Relapsed/Refractory CLL/SLL
NCT01578707Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Jun 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Pharmacyclics. Primary endpoint: Progression-Free Survival up to 6 years. Started Jun 2012; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01578707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01578707.